Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines
出版年份 2019 全文链接
标题
Oncogenic Y68 frame shift mutation of PTEN represents a mechanism of docetaxel resistance in endometrial cancer cell lines
作者
关键词
-
出版物
Scientific Reports
Volume 9, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-02-14
DOI
10.1038/s41598-019-38585-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The Molecular Biology of Endometrial Cancers and the Implications for Pathogenesis, Classification, and Targeted Therapies
- (2017) Nisha Bansal et al. Cancer Control
- PI3K/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1-α/VEGF pathway in endometrial cancer
- (2015) Aki Miyasaka et al. GYNECOLOGIC ONCOLOGY
- Sequential Chemotherapy and Radiotherapy in the Sandwich Method for Advanced Endometrial Cancer
- (2015) Huiqiao Gao et al. MEDICINE
- Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer
- (2014) Hui Jun Lim et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines
- (2013) B. Weigelt et al. CLINICAL CANCER RESEARCH
- The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis
- (2013) Hyun Jong Park et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells
- (2013) G. E. Konecny et al. MOLECULAR CANCER THERAPEUTICS
- Integrated genomic characterization of endometrial carcinoma
- (2013) Gad Getz et al. NATURE
- The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer
- (2012) B. M. Slomovitz et al. CLINICAL CANCER RESEARCH
- Contemporary management of endometrial cancer
- (2012) Jason D Wright et al. LANCET
- Markers for individualised therapy in endometrial carcinoma
- (2012) Helga B Salvesen et al. LANCET ONCOLOGY
- The functions and regulation of the PTEN tumour suppressor
- (2012) Min Sup Song et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- G2 checkpoint abrogator abates the antagonistic interaction between antimicrotubule drugs and radiation therapy
- (2012) Meihua Sui et al. RADIOTHERAPY AND ONCOLOGY
- Emerging therapeutic targets in endometrial cancer
- (2011) Konstantin J. Dedes et al. Nature Reviews Clinical Oncology
- High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
- (2011) Lydia W.T. Cheung et al. Cancer Discovery
- Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer–Results from two randomised studies
- (2010) Thomas Hogberg et al. EUROPEAN JOURNAL OF CANCER
- A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the “sandwich” method for high risk endometrial carcinoma
- (2010) Melissa A. Geller et al. GYNECOLOGIC ONCOLOGY
- Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
- (2008) G E Konecny et al. BRITISH JOURNAL OF CANCER
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pilot phase II trial of radiation “sandwiched” between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC)
- (2007) Abbie L. Fields et al. GYNECOLOGIC ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation